Bidirectional Mendelian randomization analysis and systematic meta-analysis of causal relationships between hepatocellular carcinoma and non-alcoholic fatty liver disease.
[BACKGROUND] The causal relationships between hepatocellular carcinoma (HCC) and non-alcoholic fatty liver disease (NAFLD) remain unclear.
- p-value P < 0.0001
- 95% CI 2.11-7.55
- HR 3.99
- 연구 설계 meta-analysis
APA
Zhao T, Lou Y (2025). Bidirectional Mendelian randomization analysis and systematic meta-analysis of causal relationships between hepatocellular carcinoma and non-alcoholic fatty liver disease.. Discover oncology, 16(1), 1564. https://doi.org/10.1007/s12672-025-03350-0
MLA
Zhao T, et al.. "Bidirectional Mendelian randomization analysis and systematic meta-analysis of causal relationships between hepatocellular carcinoma and non-alcoholic fatty liver disease.." Discover oncology, vol. 16, no. 1, 2025, pp. 1564.
PMID
40817987
Abstract
[BACKGROUND] The causal relationships between hepatocellular carcinoma (HCC) and non-alcoholic fatty liver disease (NAFLD) remain unclear. This study investigated bidirectional causality between HCC and NAFLD using Mendelian randomization, and evaluated liver-related mortality risk in NAFLD patients through meta-analysis.
[METHODS] We performed bidirectional two-sample Mendelian randomization using genome-wide association study data (775 HCC cases, 1,332 controls; 8,434 NAFLD cases, 770,180 controls). Multiple analytical methods included inverse variance weighted, MR-Egger, and weighted median approaches. Meta-analysis included 8 studies with 577,921 participants examining liver-related mortality in NAFLD versus non-NAFLD populations.
[RESULTS] Mendelian randomization analysis revealed no significant causal relationships between HCC and NAFLD in either direction, with effect estimates consistently clustering around zero across all methods. Meta-analysis demonstrated significantly increased liver-related mortality risk in NAFLD patients (HR = 3.99, 95% CI: 2.11-7.55, P < 0.0001) with substantial heterogeneity (I² = 92.9%).
[CONCLUSION] This study provides evidence against strong bidirectional causal relationships between genetic predisposition to HCC and NAFLD. However, NAFLD patients show a four-fold increased risk of liver-related mortality, highlighting the clinical importance of NAFLD as a predictor of adverse liver outcomes.
[METHODS] We performed bidirectional two-sample Mendelian randomization using genome-wide association study data (775 HCC cases, 1,332 controls; 8,434 NAFLD cases, 770,180 controls). Multiple analytical methods included inverse variance weighted, MR-Egger, and weighted median approaches. Meta-analysis included 8 studies with 577,921 participants examining liver-related mortality in NAFLD versus non-NAFLD populations.
[RESULTS] Mendelian randomization analysis revealed no significant causal relationships between HCC and NAFLD in either direction, with effect estimates consistently clustering around zero across all methods. Meta-analysis demonstrated significantly increased liver-related mortality risk in NAFLD patients (HR = 3.99, 95% CI: 2.11-7.55, P < 0.0001) with substantial heterogeneity (I² = 92.9%).
[CONCLUSION] This study provides evidence against strong bidirectional causal relationships between genetic predisposition to HCC and NAFLD. However, NAFLD patients show a four-fold increased risk of liver-related mortality, highlighting the clinical importance of NAFLD as a predictor of adverse liver outcomes.
같은 제1저자의 인용 많은 논문 (5)
- Chrysophanol attenuates breast cancer angiogenesis through blocking VEGFA/VEGFR2/ERK activation via inhibiting ACE2 ubiquitination.
- Ultrasound and ROS-responsive nanodroplets inhibit TCA cycle in hepatocellular carcinoma.
- Retraction notice to "Roles of long non-coding RNA in prostate cancer pathogenesis" [Clinical Genitourinary Cancer 22 (2024) 102213].
- Diagnostic Pitfalls of -Rearranged Perivascular Epithelioid Cell Tumor of the Kidney.
- Diagnostic Challenges in Identifying Concurrent Myeloid Sarcoma and High-Grade Prostatic Adenocarcinoma Within the Prostate.